$生物医药控股(BHVN)$ 今天宣布Troriluzole 通过中期无效性分析，可以继续临床研究，非常好的结果！！！

12/06/2019

- Troriluzole, an oral, once-daily tablet that modulates glutamate, is being studied as a symptomatic treatment for mild-to-moderate Alzheimer's disease in the T2 Protect AD Study- The independent Data Safety Monitoring Board (DSMB) completed its review of the prespecified interim futility analysis and communicated that futility was not met- In order to pass the interim futility analysis, troriluzole had to demonstrate numerically greater benefit over placebo on at least one of the two pre-specified criteria at 26 weeks: (i) cognitive function as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) or (ii) hippocampal volume as assessed by magnetic resonance imaging